Eric Ofori Aboagye is a Professor of Cancer Pharmacology and Molecular Imaging at Imperial College London. He is a Fellow of the Academy of Medical Sciences and was awarded the British Institute of Radiology Sir Mackenzie Davidson Medal in 2009. He is co-director of the Imperial College London Experimental Cancer Medicine's Centre.
Eric Aboagye | |
|---|---|
| Born | |
| Alma mater | Kwame Nkrumah University of Science and Technology (BSc) University of Strathclyde (MSc) University of Glasgow (PhD) |
| Scientific career | |
| Institutions | Johns Hopkins University Imperial College London |
| Thesis | Fluorinated 2-Nitroimidazoles: Non-Invasive Probes for Detecting Therapeutically Relevant Tumour Hypoxia by Magnetic Resonance Spectroscopy (1995) |
Early life and education edit
Aboagye was born in Ghana.[1] He studied pharmacy at the Kwame Nkrumah University of Science and Technology in 1989.[1] He moved to the United Kingdom shortly after, and completed a master's degree in pharmaceutical analysis at the University of Strathclyde.[1] He earned his doctoral degree at the Cancer Research UK Beatson Laboratories in Glasgow. He was a postdoctoral researcher at Johns Hopkins University.[2]
Research and career edit
Aboagye joined Imperial College London as a research associate in 1998.[1] He was promoted to Professor in 2006. He is interested in molecular imaging and the development of novel imaging for cancer diagnosis.[1] He is Director of the Comprehensive Cancer Imaging Centre, which combines synthetic chemistry, software development and biomedical science in an effort to diagnose and treat cancer patients.[3]
He has demonstrated that artificial intelligence is significantly more accurate than blood tests in predicting the survival rates of ovarian cancer.[4] For the study, Aboagye used TexLab to analyse CT scans and establish the health risks associated with different tumours.[4] The software was trained to analyse the shape, size, genetic composition and structure of tumours.[4] Aboagye have developed imaging tools capable of characterising choline, glycogen and fatty acid metabolism.[5]
Awards and honours edit
His awards and honours include:
- 2009 British Institute of Radiology Sir Mackenzie Davidson Medal[6]
- 2010 Elected Fellow of the Academy of Medical Sciences[3]
Selected publications edit
His publications include:
- Aboagye, Eric O. (1999). "Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells". Cancer Research. 59 (1): 80–4. PMID 9892190.
- Aboagye, Eric O. (2013). "Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer". Chemical Society Reviews. 42 (19): 7816–33. doi:10.1039/C3CS60149H. PMID 23788179.
- Aboagye, Eric O. (2003). "3′-Deoxy-3′-[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography". Cancer Research. 63.
References edit
- ^ a b c d e "Dr Eric O. Aboagye, PhD FMedSci | Speaker at PMF Cancer 2019". Precision Medicine Forum. 2019-10-21. Retrieved 2020-01-29.
- ^ "Eric Aboagye: Scientific Director, ECMC". crukimperialcentre.co.uk. Retrieved 2020-01-29.
- ^ a b "Professor Eric Aboagye | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2020-01-29.
- ^ a b c "New AI is four times more accurate at predicting ovarian cancer deaths". Digital Health. 2019-02-21. Retrieved 2020-01-29.
- ^ "Eric Aboagye PhD FMedSci" (PDF). Fundación Ramón Areces. Retrieved 2020-01-29.
- ^ "Honours and Memberships - Professor Eric Aboagye". www.imperial.ac.uk. Retrieved 2020-01-29.